




The relative strengths and weaknesses of Progenics Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Progenics Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Progenics Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 252%, being 2.4% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	144,129
Cost of Goods Sold	0
Intangible Assets	19,740
Liabilities, Current	23,446
Liabilities, Non-Current	40,998
Other Assets	1,684
Other Compr. Net Income	-72
Other Expenses	15,768
Other Liabilities	3,978
Other Net Income	-2,933
Other Revenues	15,622
Property and Equipment	3,944
Research and Development	35,147
Selling, General and Administrative Expense	29,431

Output Variable	Value in 1000 USD
Assets	169,497
Liabilities	68,422
Expenses	80,346
Revenues	15,622
Stockholders Equity	101,075
Net Income	-67,657
Comprehensive Net Income	-67,693
BaseVar	168,446
ECR before LimitedLiability	128%
Economic Capital Ratio	252%